• Earlier this month, VEON Ltd. filed a shelf registration for up to US$5.16 billion in common shares, covering 94,411,725 shares in connection with an ESOP-related offering.
• This sizable shelf capacity gives VEON flexibility to issue a large volume of equity over time, which may influence how investors assess potential dilution, capital raising plans, and employee alignment with the company’s long-term direction.
• Next, we will examine how this large ESOP-related shelf registration could reshape key elements of VEON’s existing investment narrative.

Find 63 companies with promising cash flow potential yet trading below their fair value.

VEON Investment Narrative Recap

To own VEON today, you need to believe that its digital-first push across Pakistan, Ukraine, Kazakhstan, Uzbekistan, and Bangladesh can offset macro, currency, and competitive pressures. The new US$5.16 billion ESOP-related shelf does not immediately change the key near term catalyst, which is execution on digital growth and guidance, but it could sharpen focus on dilution risk and balance sheet flexibility, especially given existing leverage and refinancing needs.

The recent 2025 results and 2026 guidance, with full year revenue of US$4,399 million and net income of US$532 million, are the most relevant backdrop for this shelf filing. Analysts were already watching how VEON converts digital payments scale, such as JazzCash’s more than US$53 billion in 2025 transaction value, into sustained earnings quality. The ability to issue ESOP shares now sits alongside those operational milestones as another factor investors will weigh in the months ahead.

Yet the real question investors should be aware of is how this equity capacity interacts with VEON’s already high debt and refinancing exposure...

VEON's narrative projects $5.2 billion revenue and $726.3 million earnings by 2029.

Uncover how VEON's forecasts yield a $80.48 fair value, a 52% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already more cautious, assuming only about US$4.7 billion of revenue and US$560.7 million of earnings by 2028, and this large ESOP shelf could become another test of their concern about refinancing and balance sheet risk if future capital raising or dilution plays out differently than consensus expects.

Explore 6 other fair value estimates on VEON - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your VEON research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free VEON research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate VEON's overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.